Literature DB >> 27504758

Genentech's PD-L1 agent approved for bladder cancer.

Mark Ratner.   

Abstract

Entities:  

Year:  2016        PMID： 27504758     DOI： 10.1038/nbt0816-789

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  1 in total

1.  Predictive biomarkers for checkpoints, first tests approved.

Authors:  Ken Garber
Journal:  Nat Biotechnol       Date:  2015-12-09       Impact factor: 54.908
  1 in total
  3 in total

1.  Fresh from the biotech pipeline-2016.

Authors:  Chris Morrison
Journal:  Nat Biotechnol       Date:  2017-01-30       Impact factor: 54.908

Review 2.  Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy.

Authors:  Kenneth M Felsenstein; Dan Theodorescu
Journal:  Nat Rev Urol       Date:  2017-11-14       Impact factor: 14.432

3.  Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy.

Authors:  Anuja Sathe; Géraldine Chalaud; Immanuel Oppolzer; Kit Yeng Wong; Margarita von Busch; Sebastian C Schmid; Zhichao Tong; Margitta Retz; Juergen E Gschwend; Wolfgang A Schulz; Roman Nawroth
Journal:  PLoS One       Date:  2018-01-22       Impact factor: 3.240
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.